If I saw this as someone who knew nothing about BIT - then I...

If I saw this as someone who knew nothing about BIT - then I would be truly impressed.

There is an old saying "if one finds they are flogging a dead horse, the best option is to dismount"

"progress in early stage" There are no active trials being undertaken at the moment.

Once again, C14 is the carrot being proffered to SH. At what stage will the C14 option be seen as a non event and abandoned to save funds?

Biotron Limited (ASX: BIT) Chairman Michael Hoy & Managing Director Michelle Miller will
conduct an Investor Webinar on 11am AEDT on Tuesday 04 March 2025 to outline Biotron’s latest
developments and commercial trajectory:
• BIT225 HIV-1 Phase 2 Clinical Trials Met Primary Objectives:
o BIT225 was safe and generally well tolerated with no deaths or drug-related adverse
events.
o BIT225 treated cleared virus faster than those on ART alone.
o BIT225 induced statistically significant changes in specific immune cell populations,
markers and cytokines.
• Progress in Early-Stage Programs – Advances in Hepatitis B and Dengue Virus programs
reinforce Biotron’s potential across multiple infectious diseases.
• Commercialisation Strategy – Ongoing collaboration with US-based C14 Consulting
Group to secure strategic partnerships, commercialise clinical and pre-clinical assets,
including platform technologies.
• Share Purchase Plan (SPP) – Offering eligible shareholders an opportunity to participate in
Biotron’s growth at $0.01 per share.